| Release of platelet-activating factor in systemic lupus erythematosus. | |
| | |
MedLine Citation:
|
PMID: 2354868 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The biologically active 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor; PAF) is inactivated in plasma mainly by a specific PAF acetylhydrolase (1-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine acetylhydrolase; EC 3.1.1.48). In the present study, PAF was released in detectable amounts (5.4 +/- 2.9 ng/ml; mean +/- 1 SD) in the plasma of 8 out of 10 patients with systemic lupus erythematosus (SLE) during the most active phases of the disease. PAF was never detectable in the plasma of patients with inactive SLE or of healthy subjects. PAF acetylhydrolase activity was markedly reduced in sera of 10 patients with active SLE as compared to 7 patients with inactive SLE, 16 patients with rheumatoid arthritis (RA), 5 patients with nephrotic syndrome (NS) and 15 healthy subjects. A kinetic study of the enzyme in patients with active SLE suggested an overall reduced activity rather than an intrinsic defect of the enzyme. PAF acetylhydrolase in sera of patients with active SLE shared with that of healthy subjects the same substrate specificity, sensitivity to enzymatic and chemicophysical treatments and association to low-density lipoprotein (LDL), acting as carrier of PAF acetylhydrolase in plasma. However, the protein concentration of LDL was significantly reduced in patients with active SLE as compared to patients with inactive SLE, RA and NS and to healthy subjects, thereby suggesting that the reduction of PAF acetylhydrolase activity in active SLE might be due at least in part to a carrier defect related to the activity of the disease. In addition, experiments in which serum of patients with active SLE and serum of healthy subjects were mixed in different combinations indicated the absence of factors inhibiting PAF acetylhydrolase activity in SLE patients. |
| | |
Authors:
|
C Tetta; F Bussolino; V Modena; G Montrucchio; G Segoloni; G Pescarmona; G Camussi |
Related Documents
:
|
3717808 - Total lymphoid irradiation in refractory systemic lupus erythematosus. 6249928 - Neuropsychiatric lupus. 1259798 - Effect of aspirin on liver tests in patients with ra or sle and in normal volunteers. 15226518 - The use of the british isles lupus assessment group (bilag) index as a valid tool in as... 11114448 - Graphical presentation of the range of hip and knee rotations for clinical evaluation o... 12882388 - In refractory temporal lobe epilepsy, consider surgery sooner. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: International archives of allergy and applied immunology Volume: 91 ISSN: 0020-5915 ISO Abbreviation: Int. Arch. Allergy Appl. Immunol. Publication Date: 1990 |
Date Detail:
|
Created Date: 1990-07-24 Completed Date: 1990-07-24 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0404561 Medline TA: Int Arch Allergy Appl Immunol Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 244-56 Citation Subset: IM |
Affiliation:
|
Laboratorio di Immunopatologia, Università di Torino, Italia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
1-Alkyl-2-acetylglycerophosphocholine Esterase Adolescent Adult Aged Female Half-Life Humans Kinetics Lipoproteins, HDL / isolation & purification Lipoproteins, LDL / isolation & purification Lipoproteins, VLDL / isolation & purification Lupus Erythematosus, Systemic / blood*, enzymology Male Middle Aged Phospholipases / blood* Phospholipases A / blood*, isolation & purification |
| Chemical | |
Reg. No./Substance:
|
0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Lipoproteins, VLDL; EC 3.1.-/Phospholipases; EC 3.1.1.-/Phospholipases A; EC 3.1.1.47/1-Alkyl-2-acetylglycerophosphocholine Esterase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of Toxocara canis infection on hemopoietic stem cells and hemopoietic factors in mice.
Next Document: Morphological basis for impaired protective efficiency by the nasal mucosa in infants with and witho...